The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans.
about
Roles of Autophagy and Autophagy-Related Proteins in Antifungal ImmunityDancing cheek to cheek: Cryptococcus neoformans and phagocytesHost immunity to Cryptococcus neoformansAntifungal Th Immunity: Growing up in FamilyAdrenergic-mediated loss of splenic marginal zone B cells contributes to infection susceptibility after strokeImmunoglobulin M antiplatelet autoantibodies from mice immunized with rat platelets induce thrombocytopenia and platelet function impairment.The long elusive IgM Fc receptor, FcμR.Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina.Epidemiology of cryptococcal meningitis in the US: 1997-2009.Ten challenges on Cryptococcus and cryptococcosis.Manipulation of the glycan-specific natural antibody repertoire for immunotherapyIL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms.Antigen-driven induction of polyreactive IgM during intracellular bacterial infection.Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models.The Cnes2 locus on mouse chromosome 17 regulates host defense against cryptococcal infection through pleiotropic effects on host immunityAltered Ig levels and antibody responses in mice deficient for the Fc receptor for IgM (FcμR).Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection.Mouse IgM Fc receptor, FCMR, promotes B cell development and modulates antigen-driven immune responses.A new synthesis for antibody-mediated immunity.X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection.Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal diseaseIdentification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responsesInduction of protective immunity against cryptococcosis.Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.Protective autoantibodies in the rheumatic diseases: lessons for therapy.Primary selective IgM deficiency: an ignored immunodeficiency.Cryptococcus antigens and immune responses: implications for a vaccine.The protective role of immunoglobulins in fungal infections and inflammation.Immunity to Cryptococcus neoformans and C. gattii during cryptococcosisNaïve B cells reduce fungal dissemination in Cryptococcus neoformans infected Rag1(-/-) mice.sIgM-FcμR Interactions Regulate Early B Cell Activation and Plasma Cell Development after Influenza Virus Infection.Innate host defenses against Cryptococcus neoformans.Reconstituted human polyclonal plasma-derived secretory-like IgM and IgA maintain the barrier function of epithelial cells infected with an enteropathogen.FcμR in human B cell subsets in primary selective IgM deficiency, and regulation of FcμR and production of natural IgM antibodies by IGIV.Determining the phagocytic activity of clinical antibody samples.Defining Natural Antibodies.EVALUATION OF EXPERIMENTAL INFECTION WITH L. (L.) AMAZONENSIS IN X-LINKED IMMUNODEFICIENT MICE.Capsular specific IgM enhances complement-mediated phagocytosis and killing of Cryptococcus neoformans by methamphetamine-treated J774.16 macrophage-like cells.Analysis of subsets of B cells, Breg, CD4Treg and CD8Treg cells in adult patients with primary selective IgM deficiencyCommentary: Role of Sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development.
P2860
Q26765850-A895731F-C58C-4711-B9FA-483036FB7343Q26798926-AF13E8A6-506B-4EE5-A799-10A2218C93F2Q26823438-4EA56001-6AF9-466F-B8AB-29AF2546EB9FQ27002920-706F7102-A7DF-42FE-AB8A-5048A213A327Q30846614-DBCF11E2-B06E-4276-9FBB-E2495ED8EC48Q33393120-97FD0AA2-8943-4E8F-9514-323F62385243Q34159967-EEAAC329-83C8-4228-8257-FE68CD29AB6DQ34420814-E6A3C3A4-0AB5-4DCA-81DA-633101372E5FQ34606681-3FE34A58-7590-44A3-87D6-0A48A2A62376Q34960987-0D6913F4-B5C3-45E5-BF83-95B9B5316315Q35920081-329C66AC-B806-4A54-A7B8-315BBF6141FAQ35952109-85278996-4296-4BDE-849B-9130C8D94664Q36106473-5BEC4019-8B8C-4C9E-BBCA-94205D0197FDQ36192774-62B63873-E4D2-47FB-9C0F-BD7E9EEC1B26Q36281331-4AEB3C8F-5DB1-4448-8645-210916D67E04Q36300670-2F7776F7-A839-4D70-AA81-FE1D28EB3673Q36456615-950A7A39-4161-4571-B992-D13ECB48E423Q36553232-9D0D8AAC-6B24-429F-88AE-439AE181F9B2Q36660720-80FE4DE1-9776-461B-B839-CA92BB7A79E8Q36994373-8D37C4F3-9FA2-4EBB-B770-B929218D0F3AQ37140093-3020B7C5-7C09-4673-B70D-B0E7422BC5F1Q37562226-524B215C-0087-4761-8598-876B24DC02B9Q37965038-AA96C2B0-1404-43E7-9403-6D2872FFE6FFQ38011299-DE81A079-F2B9-442B-BA66-4DCDAD790C93Q38090919-7E110CA9-D868-4410-80CD-19124639E04AQ38113974-AC49C22E-8F5B-4131-8391-69E3AA153CC1Q38155197-E6F63155-1382-43E5-8FF2-1BA47064B756Q38268922-5829A499-F4D0-42C6-9D22-D518233BD500Q38286732-99E9C551-CB1A-4659-BF49-C1BA038DDB74Q38610229-354C1C9F-EF54-462A-BA73-81A0CF3CDEBEQ38659471-88D045C9-CD05-467A-A678-42B4A4F532B0Q38752388-B96BD523-85EE-477E-970E-A05C984A241BQ39172391-2EA7165A-C54D-4C6E-84A5-C333FEE8C9E2Q39280258-3948C9E4-700F-4C50-A907-43E766EE3372Q39432766-814757D6-EA3A-459E-8A05-38C15C4BD9A9Q40097746-CFD85E04-2FBA-46F5-AAE8-20D432C31065Q40103940-35563518-5988-4D9F-802E-3D74DCA64015Q40196514-93D7E40A-8DDF-4F96-8DB4-1D32FF7FFAB0Q40678807-24D9EB58-33D8-472A-A814-CC549FC522F9Q41069532-2B92AFE0-7D20-4FEE-9416-F845F50E088B
P2860
The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The absence of serum IgM enhan ...... with Cryptococcus neoformans.
@ast
The absence of serum IgM enhan ...... with Cryptococcus neoformans.
@en
type
label
The absence of serum IgM enhan ...... with Cryptococcus neoformans.
@ast
The absence of serum IgM enhan ...... with Cryptococcus neoformans.
@en
prefLabel
The absence of serum IgM enhan ...... with Cryptococcus neoformans.
@ast
The absence of serum IgM enhan ...... with Cryptococcus neoformans.
@en
P2093
P2860
P356
P1476
The absence of serum IgM enhan ...... e with Cryptococcus neoformans
@en
P2093
Catherine Manix
Eric Quintero
Krishanthi S Subramaniam
Matthew S Marks
P2860
P304
P356
10.4049/JIMMUNOL.0901638
P407
P577
2010-04-19T00:00:00Z